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Expression of the cholecystokinin (CCK), gastrin and enkephalin A genes were studied by Northern blot analysis and a library of sequence-specific 
radioimmunoassays in human cell lines. The human small-cell ung carcinoma line (SCLC) U-1690 expressed moderate levels of CCK mRNA as 
compared to the human neuroepithelioma cell line SK-N-MC. Neither gastrin nor (pro)enkephalin A mRNAs were detectable in the U-1690 cell 
line. In contrast, the SCLC-line H-69 expressed Enk A but no CCK mRNA. The radioimmunoassays showed that the CCK mRNA transcript 
in the SCLC line U-1690 also is translated, and that preproCCK is processed into bioactive, carboxyamidated CCK peptides. Thus, the human 
small cell carcinoma cell line U-1690 is a useful model for studies of cell-specific CCK gene expression. 
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1. INTRODUCTION 
Bioactive cholecystokinin (CCK) peptides are 
generated by multiple proteolytic cleavages and 
derivatizations of a precursor polypeptide [ 1,2]. The 
peptides are synthesized in a cell-specific manner in the 
intestinal tract, the central nervous system [3-51, the 
pituitary [6] and in male germ cells [7]. The biogenesis 
of CCK and its regulation are difficult to investigate in 
tissues as complex as the brain or endocrine glands. 
Thus, several groups have investigated clonal cell lines 
which express CCK and gastrin at the transcriptional 
and translationaVposttranslationa1 level [8-l 31. In 
earlier studies we found that the human neuroepithe- 
lioma cell line SK-N-MC co-expresses cholecystokinin 
and proenkephalin A mRNA and that these mRNA 
levels are differently modulated by CAMP and 
noradrenalin [13]. ProCCK [I 11, proenkephalin A [12] 
and proNPY [14] prohormone processing however ap- 
pears to be incomplete in this cell line. 
More recently it has been suggested that cultured 
human colon tumour cells express and mature 
CCK/Gastrin peptides, which play an important role in 
autocrine growth stimulation [ 151, whereas opioid pep- 
tides such as Met-enkephalin inhibit cell proliferation 
[16,17]. 
In this study we report that the human small-cell ung 
carcinoma (SCLC) cell line U-1690 [18] expresses the 
CCK-gene both at the transcriptional and translational 
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level. Moreover, the translational product appears to be 
fully processed to bioactive, carboxyamidated CCK 
peptides. 
2. MATERIALS AND METHODS 
2.1. Ceil lines 
The cell lines investigated in this study were: SK-N-MC (human 
neuroepithelioma), SH-SY-SY (human neuroblastoma), IM-9 
(human lymphocytes), U-1752 (human squamous cell, SQC), U-1819 
(human large-cell ung carcinoma, LCLC), H-69, U-1285, U-1906, 
U-2020 and U-2050 (human small-cell ung carcinoma, SCLS). SQC, 
LCLC, SCLC and IM-9 cell lines or cell pellets were obtained from 
Dr. J. Bergh, University Hospital Uppsala 118). Cell lines were 
cultured in Falcon flasks either in RPMI-1640 medium (GIBCO) sup- 
plemented with 10% fetal calfserum (SEROMED), 1.76 g/l NaHCOs; 
2.38 g/l Hepes; 290 mg/l L-glutamine and 10 ml/l Penicillin- 
Streptomycin (10.000 U and 10.000 kg/ml) at 37°C under 5% carbon 
dioxide, grown to confluence and harvested prior to RNA extraction. 
SK-N-MC, SH-SY-SY, U-1752 and U-1810 cells, however, were 
cultured in Eagle’s medium supplemented as described above. 
2.2. Control material 
Rat brain and the rat medullary carcinoma cell line CA-77, which 
are known to express CCK mRNA were used in this study as positive 
controls. 
2.3. Preparation of RNA and Northern blot analysis 
Total RNA from lo7 cells was extracted by the method of Chomc- 
zynski and Sacchi [19] and quantitated by UV absorption at 260 nm. 
The RNA preparations were routinely checked for degradation on an 
agarose minigel. Poly A ’ RNA was prepared from total RNA accor- 
ding to the procedure of Aviv and Leder [20]. Electrophoretic separa- 
tion of the RNA in a denaturating agarose gel was carried out accor- 
ding to Kroczek and Siebert [21], followed by transfer onto Amer- 
sham Hybond-N membrane in 15 mM Na-phosphate, pH 6.4. Filters 
were either fixed by UV illumination in a Stratalinker (Stratogene) 
U.V.-box (Autocrosslink) or by backing under vacuum at 80°C for 
2 h. 
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2.4. Hybridization, DNA templates and cRNA probes 
Prehybridization, hybridization and subsequent autoradiography 
to Amersham MP X-ray films were carried out as reported [22]. The 
construction and in vitro transcription of the human ppENK-A and 
rat ppCCK DNA templates were recently described 112,131. The 
human gastrin DNA template was constructed by subcloning a 280 bp 
HindIIl/ExonIII-DNA fragment [23] into the Hind111 site of 
pGEM-3 vector (Promega Inc.). The @-Actin template was obtained 
by subcloning a - 1150 bp &t-DNA fragment [24] into vector 
pGEM-3. For each hybridization probe, - 1 pg DNA template was 
in vitro transcribed either by RNA polymerase T7 or SP-6, using Pro- 
megas Riboprobe-Kit and 50 pCi [32P]~-UTP (400 Ci/mmol). 
2.5. Radioimmunoassay 
In order to measure biologically active forms of CCK and gastrin, 
washed cell pellets were extracted and analyzed with a library of se- 
quence specific antisera [25]. Antiserum 2609 is directed against the 
common or-amidated C-terminus of CCK and gastrin, whereas an- 
tiserum 2604 is specific for carboxyamidated gastrins. Thus, an- 
tiserum 2604 discriminates between CCK and gastrin peptides. An- 
tiserum 8017 is directed against the N-terminal part of human 
gastrin-17. Finally, antiserum 3208 recognizes glycine-extended CCK 
and gastrin processing intermediates. By prior treatment of the 
samples with trypsin and carboxypeptidase B, antiserum 3208 also 
recognizes unprocessed proCCK peptides. 
3. RESULTS AND DISCUSSION 
The expression of the CCK, gastrin, and enkephalin 
A gene in established cell lines was investigated by Nor- 
thern blot analysis using CCK, gastrin, and enkephalin 
A complementary RNA ([32P]-labelled cRNA) 
hybridization probes. Initially, total RNA (15 pg) from 
SCLC cell lines U-1690 and U-1906, the human 
neuroepithelioma line SK-N-MC and the human 
neuroblastoma cell line SH-SY-SY was analyzed for the 
expression of gastrin and CCK mRNA. As a positive 
control, the CCK mRNA expressing rat medullary 
thyroid carcinoma cell line CA-77 and rat brain were in- 
cluded. Northern blot analysis and subsequent exposure 
of the nylon membrane to an Amersham MP-X-ray 
film for 3 days revealed that beside the SK-N-MC cell 
line and rat brain only the SCLC line U-1690 expressed 
a -750 nt CCK mRNA transcript (Fig. 1). It appears 
that CA-77 and SK-N-MC cells hyperexpressed CCK 
mRNA whereas the level of CCK mRNA seems to be 
more moderate in the U-1690 line. 
In many cases, neuropeptide mRNA expression ap- 
pears to be low and any specific transcript may only be 
detectable in poly A+ selected mRNA fractions. To test 
this possibility, poly A+ RNA from 11 different 
established cell lines, including eight lung carcinoma 
lines (see Materials and Methods) were analyzed. Thus, 
3 pg poly A + selected mRNA from the indicated cell 
lines was electrophoretically separated and transferred 
by capillary blotting to HybondN membranes. Filters 
were stepwise hybridized with gastrin, CCK, enkephalin 
A and @Actin 32P-labelled cRNA hybridization probes. 
A - 750 nt CCK mRNA transcript was found to be ex- 
pressed only in SK-N-MC and U-1690 cells (Fig. 2), 







Fig. 1. Detection of ppCCK mRNA in rat medullary thyroid 
carcinoma cell line CA-77 (lane l), human neuroepithelioma cell line 
SK-N-MC (2), human small cell lung carcinoma cell lines U-1690 (3) 
and U-1906 (4), rat brain (5). 15 fig total RNA was analyzed by 
Northern blot. Exposure was to Amersham MP X-ray film for 3 days 
at - 70°C using a DuPont intensifier screen. The positions of 28s and 
18s rRNA and ppCCK mRNA (CCK) are indicated. 
In a recent study [26], we have shown that the gastrin 
gene rather than the CCK-gene is expressed in human 
bronchogenic carcinomas. This would suggest that 
established SCLC cell lines may express the gastrin 
gene. 
Therefore, the findings that none of the investigated 
lung carcinoma cell lines expressed gastrin mRNA is 
rather unexpected. One explanation could be that the 
small quantities of somatostatin produced by the 
analyzed SCLC, and non-SCLC cell lines [18] inhibit 
the expression of the gastrin gene. In dog antral 
mucosa, somatostatin stimulates gastrin mRNA turn- 
over drastically [27]. On the other hand, gastrin mRNA 
levels might be very low and nondetectable under the 




Fig. 2. Detection of ppCCK, ppENK-A, and P-Action mRNA. 3 fig 
poly A+ mRNA was analyzed by Northern blot. The Nylon 
membrane was stepwise hybridized with human ppGastrin, rat 
ppCCK, human ppENK A, and mouse @-Actin cRNA probes. 
Exposure was to Amersham MP X-ray film for 3 days (lanes l-7) and 
2 days (lanes 8-11). The tested cell lines are; U-1285 (l), U-1690 (2), 
U-1752 (3), U-1810 (4), U-1906 (5), U-2020 (6), U-2050 (7), H-69 (8), 
SK-N-MC (9), SH-SY-5Y (lo), IM-9 (11). The positions of ppCCK 
(CCK), ppENK A(ENK), and &Actin(Ac) mRNA are indicated. 
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the occurrence of gastrin and CCK peptides in U-1690 
cell pellets. Using a library of sequence-specific gastrin 
and CCK antisera (see Materials and Methods), we 
found in U-1690 cells that the CCK mRNA transcript is 
translated and processed into a-carboxyamidated CCK 
(113,3 f 17,0 pmol/l (n = 3) and glycine-extended CCK 
peptides (64,2 + 11,9 pmol/l). Analysis of the U-1690 
cell media revelaed that at least part of the cellular CCK 
peptides was released into the medium (29,4 + 5,8 
pmol/l, n = 12). We were not able to detect gastrin pep- 
tides, thus confirming the results obtained by Northern 
blot analysis. 
In SK-N-MC cells, CCK and enkephalin A mRNA 
are co-expressed but differently modulated by 
noradrenalin and CAMP [ 131. Rehybridization of a poly 
A + membrane with a human enkephalin A cRNA 
hybridization probe revealed that only the SK-N-MC 
cell line co-expressed CCK and enkephalin A mRNA 
(Fig. 2). Interestingly, the SCLC line H-69 expressed an 
- 1400 nt enkephalin A mRNA transcript but at a more 
moderate level as compared to the SK-N-MC cell line 
(Fig. 2). White et al. recently showed that human 
SCLC-lines not only express the POMC gene but also 
secrete ACTH into the medium [28]. Thus, it seems to 
be a common feature that many SCLC cell lines express 
different opioid peptide genes. Moreover, there is 
evidence that both CCK, gastrin as well as opioid pep- 
tides play an important role in autocrine growth regula- 
tion of colon cancer cells [15], neuroblastomas [16], 
and lung cancer cells [ 171. Thus, it becomes evident that 
regulation and modulation of neuropeptide gene ex- 
pression both at the transcriptional, translational and 
posttranslational level are indeed important steps in the 
whole cascade of neuropeptide gene expression. 
In summary we find that the human SCLC cell lines 
U-1690 and H-69 as well as the epithelioma line SK-N- 
MC, all differently expressing either the CCK or the 
Enkephalin A gene, provide useful model systems to 
study cell specific neuropeptide gene expression at the 
transcriptional, translational and posttranslational 
level. 
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